Soleno therapeutics inc (SLNO)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Jun'14Mar'14
Cash flows from operating activities:
Net loss

-29,602

-30,774

-15,886

-19,511

-16,561

-13,335

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-11,763

-12,065

-12,296

-12,840

-7,446

-15,908

0

0

0

0

0

Loss from discontinued operations

-

-

-

-

-

-1,494

-1,908

-2,775

-3,265

-3,593

0

0

0

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations

-

-

-

-

-

-11,841

-16,433

-16,616

-13,037

-11,792

0

0

0

-

-

-

-

-

-

-

-

-

-

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

1,958

1,958

1,958

1,958

1,960

1,963

2,055

2,024

1,984

1,611

1,046

543

117

18

-47

24

15

10

0

0

0

0

0

Noncash lease expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

969

825

1,062

1,121

1,170

1,263

862

854

1,081

880

0

0

0

-

-

-

-

-

-

-

-

-

-

Board fees paid with common stock

-

-

-

-

-

-

280

301

315

278

219

137

69

24

0

0

0

-

-

-

-

-

-

Stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

677

-

0

0

0

0

0

Change in fair value of stock warrants

1,632

6,964

-3,001

2,572

1,560

-522

2,205

3,617

453

685

0

0

0

-

-

-

-

-

-

-

-

-

0

Change in fair value of contingent consideration

667

289

395

595

345

567

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

0

0

0

-

-

Loss on disposition of property & equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Inducement charge for Series C warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,049

0

0

0

-

-

Change in fair value of common stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

Non-cash expense of issuing shares to Aspire Capital

-

-

-

-

-

-

-

-

-

602

602

602

602

0

0

0

0

-

-

-

-

-

-

Operating loss on minority interest investment

-

-478

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense relating to warrants and convertible promissory notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Change in operating assets and liabilities:
Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

179

-

0

0

0

0

0

Inventory

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

446

-

0

0

0

-

-

Other receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Prepaid expenses, other current assets and other assets

77

-10

48

97

54

60

56

3

162

97

-240

-76

-121

-87

1

-148

-35

-77

0

0

0

0

0

Due from related party

-

-64

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

2,222

1,061

438

707

164

249

571

580

804

191

-180

-195

-907

-76

-641

-758

-7

-435

0

0

0

0

0

Accrued compensation

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued clinical trial site costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation and other liabilities

-

-

-

-

-

-

163

75

-281

-78

0

0

0

-

-

-

-

-

-

-

-

-

-

Accrued compensation and other current liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

Other long-term liabilities

-

-

-

-

-

-

-

-

-

-40

-31

-48

-47

40

52

64

72

0

0

0

0

-

-

Net cash used in continuing operating activities

-

-

-

-

-

-10,322

-8,943

-7,981

-7,603

-6,919

0

0

0

-

-

-

-

-

-

-

-

0

0

Net cash used in discontinued operating activities

-

-

-

-

-

-1,361

-1,736

-2,064

-2,684

-3,031

0

0

0

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-19,347

-17,375

-16,035

-13,993

-12,850

-11,683

-10,679

-10,045

-10,287

-9,950

-9,906

-10,649

-11,696

-13,497

-14,187

-14,262

-12,474

-10,299

0

0

0

-

-

Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Purchases of property and equipment

-

21

0

0

0

-

-

-

-

-

-

-

-

14

18

48

62

44

0

0

0

-

-

Net cash provided by (used in) continuing investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash used in discontinued investing activities

-

-

-

-

-

-

-

-

-

716

0

0

0

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

528

0

0

0

-

-

-

-

154

139

-3

-23

-38

-70

-1,328

-1,338

-1,320

0

0

0

-

-

Cash flows from financing activities:
Principal paid on finance lease liabilities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of common stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

293

0

0

0

-

-

Proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

10,000

9,930

9,930

10,000

0

0

0

0

-

-

-

-

-

-

Cash paid for the issuance of common stock and common stock warrants

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of credit line

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

101

0

0

0

-

-

Net proceeds from issuance of Convertible Preferred

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

Cash paid for the issuance cost of common stock and common stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

575

0

0

0

-

-

Net cash provided by continuing financing activities

-

-

-

-

-

-

-

-

13,833

23,945

0

0

0

-

-

-

-

-

-

-

-

-

-

Net cash provided by discontinued financing activities

-

-

-

-

-

1,525

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in financing activities

0

-

-

-

-

17,827

15,695

14,995

14,458

24,170

10,000

15,698

15,768

10,768

14,952

10,563

10,775

9,157

0

0

0

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,768

694

-5,028

-3,037

-2,462

0

0

0

0

0

Net decrease in cash and cash equivalents

-4,332

-2,366

518

2,814

4,499

5,964

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents included in current assets held for sale

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosures of non-cash investing and financing information
Conversion of preferred to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

Patent costs included in Accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

Issuance of common stock in Essentialis acquisition

-

-

-

-

-

-

-

-

-

17,246

18,764

18,764

17,246

0

0

0

112

112

0

0

0

-

-

Contingent consideration of Essentialis acquisition

-

-

-

-

-

-

-

-

-

2,590

0

0

0

-

-

-

-

-

-

-

-

-

-

Accrued liability for cost of issuing common stock

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred convertible stock transaction costs included in Accounts Payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Fixed asset purchases in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

Costs of Essentialis acquisition included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

Contingent consideration of Essentialis acquisition

-

-

-

-

-

-

-

-

-

2,590

1,090

1,090

2,590

0

0

0

0

-

-

-

-

-

-

Reduction in initial public offering costs payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

Continuing Operations [Member]
Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

5,972

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Discontinued Operations [Member]
Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-8

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-